Clicky

Avacta Group Plc(AVCT)

Description: Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.


Keywords: Medicine Biotechnology Life Sciences Tools Immunology Clinic Immune System Antibodies Oncology Science Disorders Assay Aptamer Affimer Synthetic Antibody

Home Page: www.avacta.com

AVCT Technical Analysis

Thorp Arch Estate
Wetherby, LS23 7FA
United Kingdom
Phone: 44 1904 217 070


Officers

Name Title
Dr. David Alastair Smith CEO & Exec. Director
Mr. Tony Gardiner CFO, Company Sec. & Exec. Director
Ms. Emma Wright Group In-House Counsel
Mr. Michael Vinegrad Group Communications Director
Dr. Matt Johnson Chief Scientific Officer of Diagnostics
Dr. Neil Bell Chief Devel. Officer of Therapeutics
Dr. Fiona McLaughlin FSB, Ph.D. Chief Scientific Officer of Therapeutics Division
Mr. Marc Green Head of Product Devel. - Diagnostics
Gemma Wilson Head of QA/RA - Diagnostics
Mr. Petros Sarantos Head of Product Management - Diagnostics

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.9049
Price-to-Sales TTM: 39.0603
IPO Date:
Fiscal Year End: December
Full Time Employees: 133
Back to stocks